Key result
Intraoperative remifentanil infusion was associated with a increased average hospital length of stay compared to no remifentanil in patients undergoing abdominal surgery.
Why the study?
Remifentanil infusions are postulated to aid recovery, but evidence suggests associations with longer post-anesthetic care unit stays, higher pain, and increased analgesic requirements.
Does intraoperative remifentanil infusion reduce length of stay in adult patients undergoing elective major abdominal surgery?
Cohort (n=3,648)
No
Does intraoperative remifentanil infusion reduce length of stay in adult patients undergoing elective major abdominal surgery?
Intraoperative remifentanil during major abdominal surgery is associated with slightly increased hospital and high-dependency unit length of stay, but shorter ICU stay, questioning its cost-effectiveness for enhancing recovery.
Answers are grounded in this paper and cite their sources.
May prolong PACU stay and increase pain after abdominal surgery; leaves open whether randomized trials will confirm.
Perioperative remifentanil infusions have been postulated to help with recovery after surgery due to their rapid offset and predictable metabolism. However, evidence on patients undergoing abdominal surgery suggests an association between intraoperative remifentanil and longer length of stay in the post-anesthetic care unit, increased postoperative pain and analgesic requirement.We retrospectively evaluated 3648 adult patients who underwent major abdominal surgeries from 2013 to 2020 in a tertiary single center. Propensity score matching was conducted to balance 12 specific covariates between the treatment and control groups prior to further statistical analysis. We found that intraoperative remifentanil infusion was associated with an increased average hospital length of stay (10.62 in treatment group vs 10.13 in control group, 95% CI 0.048 - 0.088, P<0.001) and increased length of stay in the high dependency ward (1.89 days in treatment group vs 1.52 days in control group, 95% CI 0.126 - 0.223 P <0.001), but a shorter stay in the intensive care unit (4.03 hours in treatment group vs 7.01 hours in control group, 95% CI -0.509 - 0.452, P <0.001). Consistent with current evidence, there was no significant difference between the treatment and control groups for death in 3 months and 2 years post-surgery.In conclusion, our study suggests that remifentanil may not promote postoperative recovery as expected. Its role in enhancing recovery is debatable and further studies are needed to determine the cost effectiveness of remifentanil use in abdominal surgery.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2022) conducted a cohort in Elective abdominal surgeries (n=3,648). Intraoperative remifentanil infusion vs. No remifentanil was evaluated on Average hospital length of stay (days) (95% CI 0.048-0.088, p=<0.001). Intraoperative remifentanil infusion was associated with a increased average hospital length of stay compared to no remifentanil in patients undergoing abdominal surgery.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: